Inositol phosphate

Inositec Appoints Serial Entrepreneur and Cardiologist Michael H. Davidson to Board of Directors

Retrieved on: 
Wednesday, October 7, 2020
Biotechnology, Pharmaceutical, Health, Cardiology, Branches of biology, Anatomy, Biology of bipolar disorder, Valve stenosis, Medical specialties, Aortic stenosis, Inositol phosphate, Stenosis, Aortic valve, Inositol

Inositec , a pioneer in the development of life-saving small molecule drugs for calcification disorders such as aortic valve stenosis, announced today that Michael H. Davidson, MD, has been appointed to the Board of Directors.

Key Points: 
  • Inositec , a pioneer in the development of life-saving small molecule drugs for calcification disorders such as aortic valve stenosis, announced today that Michael H. Davidson, MD, has been appointed to the Board of Directors.
  • Currently CEO of New Amsterdam Pharma, Dr. Davidson was previously the founding CEO and Chief Scientific Officer of Corvidia Therapeutics, which was recently acquired by Novo-Nordisk.
  • We are truly honored to have Michael join our Board of Directors.
  • Inositec is pioneering the development of life-saving small molecule drugs based on inositol phosphate, a natural facilitator of diverse cellular functions.

Inositec Granted US Composition of Matter Patent for Cardiovascular Calcification Inhibitor INS-3001

Retrieved on: 
Monday, May 4, 2020
Biotechnology, Pharmaceutical, Health, RTT, Branches of biology, Circulatory system, Chemistry, Aortic stenosis, Calcification, Inositol phosphate, Aortic valve, Cardiovascular disease, Inositol, Valve stenosis, Monckeberg's arteriosclerosis

Calcification, particularly in arterial walls and cardiac valves, leads to high cardiovascular morbidity and mortality.

Key Points: 
  • Calcification, particularly in arterial walls and cardiac valves, leads to high cardiovascular morbidity and mortality.
  • Inositec is developing INS-3001 for a number of cardiovascular indications caused by calcification, including aortic valve stenosis.
  • U.S. patent number 10,624,909 covers specifically the composition of matter and use of inositol derivatives for conditions related to pathological calcium crystallization.
  • Inositec is pioneering the development of life-saving small molecule drugs based on inositol phosphate, a natural facilitator of diverse cellular functions.